Literature DB >> 31199711

Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.

Alberto Diaz de Leon1, Ali Pirasteh1, Daniel N Costa1, Payal Kapur1, Hans Hammers1, James Brugarolas1, Ivan Pedrosa1.   

Abstract

Locally advanced and metastatic renal cell carcinoma (RCC) present a specific set of challenges to the radiologist. The detection of metastatic disease is confounded by the ability of RCC to metastasize to virtually any part of the human body long after surgical resection of the primary tumor. This includes sites not commonly included in routine surveillance, which come to light after the patient becomes symptomatic. In the assessment of treatment response, the phenomenon of tumor heterogeneity, where clone selection through systemic therapy drives the growth of potentially more aggressive phenotypes, can result in oligoprogression despite overall disease control. Finally, advances in therapy have resulted in the development of immuno-oncologic agents that may result in changes that are not adequately evaluated with conventional size-based response criteria and may even be misinterpreted as progression. This article reviews the common challenges a radiologist may encounter in the evaluation of patients with locally advanced and metastatic RCC. ©RSNA, 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31199711      PMCID: PMC6677287          DOI: 10.1148/rg.2019180178

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  117 in total

Review 1.  Diagnosis, staging, and surveillance of pancreatic cancer.

Authors:  Eric P Tamm; Paul M Silverman; Chusilp Charnsangavej; Douglas B Evans
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

2.  Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Authors:  Shreyas S Joshi; Elizabeth A Handorf; Matthew Zibelman; Elizabeth R Plimack; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Daniel M Geynisman
Journal:  Eur Urol       Date:  2018-06-05       Impact factor: 20.096

3.  The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery.

Authors:  Brian I Rini; Jorge Garcia; Paul Elson; Laura Wood; Shetal Shah; Andrew Stephenson; Mohammed Salem; Michael Gong; Amr Fergany; John Rabets; Jihad Kaouk; Venkatesh Krishnamurthi; Eric Klein; Robert Dreicer; Steven Campbell
Journal:  J Urol       Date:  2012-03-14       Impact factor: 7.450

4.  Whole-body MRI in follow-up of patients with renal cell carcinoma.

Authors:  Ivan Platzek; Stefan Zastrow; Pierre-Emanuel Deppe; Marc-Oliver Grimm; Manfred Wirth; Michael Laniado; Christian Stroszczynski
Journal:  Acta Radiol       Date:  2010-06       Impact factor: 1.990

5.  Differentiation of papillary renal cell carcinoma subtypes on CT and MRI.

Authors:  Nathan D Egbert; Elaine M Caoili; Richard H Cohan; Matthew S Davenport; Isaac R Francis; L Priya Kunju; James H Ellis
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

Review 6.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Authors:  John S Lam; Oleg Shvarts; John T Leppert; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 8.  Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.

Authors:  Blanca Paño Brufau; Carmen Sebastià Cerqueda; Laura Buñesch Villalba; Rafael Salvador Izquierdo; Begoña Mellado González; Carlos Nicolau Molina
Journal:  Radiographics       Date:  2013-10       Impact factor: 5.333

9.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer.

Authors:  Robert L Grubb; Michael E Franks; Jorge Toro; Lindsay Middelton; Lynda Choyke; Sarah Fowler; Carlos Torres-Cabala; Gladys M Glenn; Peter Choyke; Maria J Merino; Berton Zbar; Peter A Pinto; Ramaprasad Srinivasan; Jonathan A Coleman; W Marston Linehan
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

10.  Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

Authors:  Yassir Sbitti; Hassan Seddik; Adil Debbagh; Fahd Benani; Khaoula Slimani; Mohamed Mahi; Mohamed Tarchouli; Abdelmounaim Aitali; Abderrahmane Albouzidi; Hassan Errihani; Mohamed Ichou
Journal:  World J Surg Oncol       Date:  2016-08-23       Impact factor: 2.754

View more
  4 in total

Review 1.  Use of dual-energy CT for renal mass assessment.

Authors:  Shanigarn Thiravit; Christina Brunnquell; Larry M Cai; Mena Flemon; Achille Mileto
Journal:  Eur Radiol       Date:  2020-11-18       Impact factor: 5.315

2.  Practical identifiability analysis of a mechanistic model for the time to distant metastatic relapse and its application to renal cell carcinoma.

Authors:  Arturo Álvarez-Arenas; Wilfried Souleyreau; Andrea Emanuelli; Lindsay S Cooley; Jean-Christophe Bernhard; Andreas Bikfalvi; Sebastien Benzekry
Journal:  PLoS Comput Biol       Date:  2022-08-25       Impact factor: 4.779

3.  Metastasis of renal cell carcinoma to the ure-thra: a rare scenario.

Authors:  Sofia Frade Santos; Pedro Oliveira Santos; Delfim Doutel; Jose Venancio
Journal:  Int Braz J Urol       Date:  2021 May-Jun       Impact factor: 1.541

4.  Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the ADAMTS18 gene.

Authors:  Ben Xu; Wei-Jie Zhu; Yi-Ji Peng; Si-Da Cheng
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.